Heart and Kidney Institute, Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, U.S.A.
Biosci Rep. 2019 May 23;39(5). doi: 10.1042/BSR20190429. Print 2019 May 31.
Immune cell infiltration plays a central role in mediating endotoxemic acute kidney injury (AKI). Recently, we have reported the anti-inflammatory and reno-protective role of angiotensin-II type-2 receptor (ATR) activation under chronic low-grade inflammatory condition in the obese Zucker rat model. However, the role of ATR activation in preventing lipopolysaccharide (LPS)-induced early infiltration of immune cells, inflammation and AKI is not known. Mice were treated with ATR agonist C21 (0.3 mg/kg), with and without ATR antagonist PD123319 (5 mg/kg) prior to or concurrently with LPS (5 mg/kg) challenge. Prior-treatment with C21, but not concurrent treatment, significantly prevented the LPS-induced renal infiltration of CD11b immune cells, increase in the levels of circulating and/or renal chemotactic cytokines, particularly interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) and markers of renal dysfunction (blood urea nitrogen and albuminuria), while preserving anti-inflammatory interleukin-10 (IL-10) production. Moreover, C21 treatment in the absence of LPS increased renal and circulating IL-10 levels. To investigate the role of IL-10 in a cross-talk between epithelial cells and monocytes, we performed conditioned media (CM) studies in human kidney proximal tubular epithelial (HK-2) cells and macrophages (differentiated human monocytes, THP-1 cells). These studies revealed that the conditioned-media derived from the C21-treated HK-2 cells reduced LPS-induced THP-1 tumor necrosis factor-α (TNF-α) production via IL-10 originating from HK-2 cells. Our findings suggest that prior activation of ATR is prophylactic in preventing LPS-induced renal immune cell infiltration and dysfunction, possibly via IL-10 pathway.
免疫细胞浸润在介导内毒素血症急性肾损伤(AKI)中起着核心作用。最近,我们报道了在肥胖 Zucker 大鼠模型的慢性低度炎症状态下,血管紧张素-II 型 2 受体(ATR)激活的抗炎和肾保护作用。然而,ATR 激活在预防脂多糖(LPS)诱导的早期免疫细胞浸润、炎症和 AKI 中的作用尚不清楚。在 LPS(5mg/kg)挑战之前或同时,用 ATR 激动剂 C21(0.3mg/kg)和 ATR 拮抗剂 PD123319(5mg/kg)处理小鼠。预先用 C21 处理,但不是同时处理,显著预防了 LPS 诱导的 CD11b 免疫细胞在肾脏中的浸润,循环和/或肾脏趋化因子的水平升高,特别是白细胞介素-6(IL-6)和单核细胞趋化蛋白-1(MCP-1)以及肾功能障碍的标志物(血尿素氮和蛋白尿),同时保留抗炎性白细胞介素-10(IL-10)的产生。此外,在没有 LPS 的情况下,C21 处理增加了肾脏和循环中的 IL-10 水平。为了研究 IL-10 在肾上皮细胞和单核细胞之间的交叉对话中的作用,我们在人肾近端管状上皮(HK-2)细胞和巨噬细胞(分化的人单核细胞,THP-1 细胞)中进行了条件培养基(CM)研究。这些研究表明,源自 C21 处理的 HK-2 细胞的条件培养基通过 HK-2 细胞中产生的 IL-10 减少了 LPS 诱导的 THP-1 肿瘤坏死因子-α(TNF-α)的产生。我们的发现表明,ATR 的预先激活在预防 LPS 诱导的肾免疫细胞浸润和功能障碍方面具有预防作用,可能通过 IL-10 途径。